Abstract

Diabetes-associated complications, such as retinopathy, nephropathy, cardiomyopathy, and atherosclerosis, the main consequences of long-term hyperglycemia, often lead to organ dysfunction, disability, and increased mortality. A common denominator of these complications is the myofibroblast-driven excessive deposition of extracellular matrix proteins. Although fibroblast appears to be the primary source of myofibroblasts, other cells, including endothelial cells, can generate myofibroblasts through a process known as endothelial to mesenchymal transition (EndMT). During EndMT, endothelial cells lose their typical phenotype to acquire mesenchymal features, characterized by the development of invasive and migratory abilities as well as the expression of typical mesenchymal products such as α-smooth muscle actin and type I collagen. EndMT is involved in many chronic and fibrotic diseases and appears to be regulated by complex molecular mechanisms and different signaling pathways. Recent evidence suggests that small RNAs, in particular microRNAs (miRNAs) and long non-coding RNAs (lncRNAs), are crucial mediators of EndMT. Furthermore, EndMT and miRNAs are both affected by oxidative stress, another key player in the pathophysiology of diabetic fibrotic complications. In this review, we provide an overview of the primary redox signals underpinning the diabetic-associated fibrotic process. Then, we discuss the current knowledge on the role of small RNAs in the regulation of EndMT in diabetic retinopathy, nephropathy, cardiomyopathy, and atherosclerosis and highlight potential links between oxidative stress and the dyad small RNAs-EndMT in driving these pathological states.

Highlights

  • Diabetes mellitus (DM) is one of the most common chronic diseases worldwide (Lin X. et al, 2020)

  • This review aims to summarize and discuss the available knowledge on the role of small RNAs in the regulation of endothelial to mesenchymal transition (EndMT) in diabetes-associated fibrotic complications such as retinopathy, nephropathy, cardiomyopathy, atherosclerosis, and its potential link with oxidative

  • The evidence reviewed in this article indicates that some microRNAs, e.g., miR-29, miR-200, and miR-Let7, have anti-fibrotic effects and inhibit EndMT whereas others, e.g., miR-21 and miR122, possess pro-fibrotic properties and promote EndMT

Read more

Summary

Introduction

Diabetes mellitus (DM) is one of the most common chronic diseases worldwide (Lin X. et al, 2020). Long-term hyperglycemia is the main driver of the onset and the progression of common diabetic complications, those affecting the eye, kidney, nervous system, and cardiovascular system (Deshpande et al, 2008) Such complications are secondary to structural and functional alterations of organs and tissues that are caused by an increased cellular glucose uptake (Wellen and Hotamisligil, 2005). Myofibroblasts are the key mediators of pathological ECM accumulation (Kendall and Feghali-Bostwick, 2014) These cells are normally involved in tissue repair and are subsequently removed by apoptosis at the end of the repair process. This review aims to summarize and discuss the available knowledge on the role of small RNAs in the regulation of EndMT in diabetes-associated fibrotic complications such as retinopathy, nephropathy, cardiomyopathy, atherosclerosis, and its potential link with oxidative

Objectives
Findings
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call